Vivos Therapeutics与Streeterville Capital已达成一致，将双方现有协议的有效期延长至2026年8月31日。此次延期，核心在于Streeterville Capital重申了其总额450万美元的债务转换承诺。
协议条款的延续，为Vivos Therapeutics提供了更明确的资本结构前景。债务转换安排若顺利执行，将有助于优化公司资产负债表，并为后续运营及战略推进提供关键的资金灵活性。
市场观察人士指出，此类承诺的延期与重申，通常反映了投资方对标的公司长期发展潜力的持续认可。对于Vivos Therapeutics而言，稳定的资本合作伙伴关系，在当前市场环境下显得尤为重要。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.